News – Page 1066 – Endpoints News

SIGN UP

Allergan buys an ailing Repros, bagging a women’s health drug for the pipeline

8 years ago

GSK offers encouraging data on BCMA-targeting armed antibody, setting stage for a return to late-stage cancer studies

8 years ago

In latest blow to Eli Lilly, Sanofi wins FDA OK for Humalog me-too

8 years ago

Hookipa raises $60M to fund immunotherapy R&D; Roche bags Ionis option for $45M; Regeneron fights back against ...

8 years ago

#ASH17: Spark triggers a backlash as early hemophilia A gene therapy data looks shaky

8 years ago

#ASH17: Syros eviscerated by investor backlash as lead drug flails badly in PhII

8 years ago

Can GSK’s new R&D strategy resuscitate the worst performer in Big Pharma?

8 years ago

#ASH17: Verastem's AbbVie castoff is headed for the FDA — even after missing overall survival goal

8 years ago

#ASH17: Blueprint elbows its way to center ring with early data and a plan to seek quick FDA OK

8 years ago

#ASH17: How does Novartis’ Kymriah DLBCL data stack up heading straight to a CAR-T showdown with Gilead?

8 years ago

#ASH17: The BCMA-targeted CAR-T bb2121 from bluebird and Celgene takes a star turn in the spotlight

8 years ago

#ASH17: Roche unveils stellar PhII DLBCL data for one of its top hematology drugs in the pipeline

8 years ago

#ASH17: Seattle Genetics CEO Clay Siegall has an answer for the skeptics doubting Adcetris data for Hodgkin lymphoma

8 years ago

Erytech shares crater as PhIIb AML study flops; Synlogic, Gingko collaborate on discovery work; Active Biotech forced ...

8 years ago

M&A slows to a trickle in 2017, but Big Pharma could be on deck for mega deals

8 years ago

Activists threaten to push for a sale of Alexion if execs can't jack up stock price

8 years ago

Cynthia Collins exits Human Longevity; Section 32 welcomes Michael Pellini; Silverback beefs up its C-suite

8 years ago

In a showdown with AstraZeneca, Pfizer posts solid — and very familiar — PhIII breast cancer data for talazoparib

8 years ago

Denali IPO hits a 2017 record $1.7B market valuation, raising $250M for neurodegeneration R&D

8 years ago

Sexual harassment in biotech hits home as OrbiMed’s Sam Isaly steps down in wake of STAT report

8 years ago

Gilead swoops in with $567M deal to buy CAR-T 2.0 player Cell Design Labs

8 years ago

Daniel Swisher leaves an ailing Sunesis and swoops in to lead Jazz Pharmaceuticals

8 years ago

Canada's AmorChem launches $44.2M life science fund; Neon adds $36M, Merck partnership in neoantigen drive; CRISPR ...

8 years ago

Taking on gamma delta T cells, bluebird pays $16M for TC BioPharm's tumor invading tech platform

8 years ago

First page Previous page 1063 1064 106510661067 1068 1069 Next page Last page